SINTX TECHNOLOGIES INC (SINT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$1.62-2.41%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · SINT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
During 2026, SINTX has expanded the commercial infrastructure supporting its silicon nitride orthopedic portfolio, including its FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System.
Stated in 1 of 1 supplied quarters. Management reported: “Exhibit 99.1 SINTX Announces Preliminary $2.2 Million in Q3 Revenue, Exceeding High-End Guidance Third-quarter revenue grows roughly 380% from Q2, driven by stronger-than-expected industrial sales to Fortune 500 customers; Company reiterates Q4 revenue guidance Revenue milestone also enables Company to call Class B warrants SALT LAKE CITY, Utah – October 1, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced preliminary, unaudited revenue of $2.2 million* for the third quarter ended September 30, 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company remains focused on advancing the commercialization of its silicon nitride-based medical products, expanding its distribution network and developing strategic partnerships designed to supp…”
“We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX.
Stated in a supplied disclosure. Management reported: ““We are pleased by the results of our efforts to improve manufacturing and operational efficiency in the third quarter,” said Eric Olson, Chairman and CEO of SINTX.” “Our focus now is on reliable delivery, repeat business and disciplined manufacturing costs.”
Exhibit 99.1 SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program SALT LAKE CITY, Utah – July 23, 2026 – SINTX T…
Stated in a supplied disclosure. Management reported: “Exhibit 99.1 SINTX Technologies Engages Veteran MedTech Executive Chris Lyons and Southern Metrics to Establish Strategic Opportunity Management Program SALT LAKE CITY, Utah – July 23, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced biomaterials and silicon nitride technologies for medical device and industrial applications, today announced that it has engaged Southern Metrics Consulting (“Southern Metrics”) to assist the Company in identifying, evaluating, and pursuing strategic opportunities intended to enhance stockholder value.”
Exhibit 99.1 SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement SALT LAKE CITY, Utah – August 13, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Compa…
Stated in 1 of 1 supplied quarters. Management reported: “Exhibit 99.1 SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement SALT LAKE CITY, Utah – August 13, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a company focused on advanced silicon nitride materials and medical technologies, today announced that it received written notification from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain minimum stockholders’ equity of $2.5 million.”
“Exhibit 99.1 SINTX Technologies Regains Compliance with Nasdaq Stockholders’ Equity Requirement SALT LAKE CITY, Utah – August 13, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Compa…”
Concurrent with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to purchase an aggregate of approximately 1.88 million sha…
Stated in a supplied disclosure. Management reported: “Concurrent with issuing this press release on Form 8-K, the Company also intends to deliver a Call Notice to the holders of Class B Warrants to purchase an aggregate of approximately 1.88 million shares of the Company’s Common Stock.” “Per the terms of the Warrant, the per share exercise price shall be the closing price of the Company’s Common Stock at the close of the trading day immediately preceding the date of the Call Notice; if fully exercised under the terms of the Warrant, cash proceeds could provide up to $4.0 million in additional capital, while any Warrants or portion of Warrants that the Holders fail to exercise in a timely manner will automatically expire.”
Over the trailing year it converted 1.16x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
21 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.